Ultrahuman, Click Therapeutics to launch the world’s first biomarker-driven migraine management tool

What if your smart ring could do more than count steps? What if it could help dial down the pounding in your head before it starts? That's the promise behind the Migraine PowerPlug, a new wearable-integrated feature born from a partnership between Ultrahuman and Click Therapeutics. This isn't just another health tracker with pretty graphs. It's built on FDA-authorized digital therapeutic technology used in real migraine care and combines it with real-time biometric signals from your body.

For the billion people around the world who live with migraine — especially women, who suffer nearly three times more often than men — this is more than tech hype. It's a leap toward everyday support that reaches beyond the clinic and into daily life.

How does it work?

The Migraine PowerPlug plugs right into the Ultrahuman platform, feeding on the wearable's suite of biometric data. Here's the short version of what it does:

• Tracks key physiological signals like sleep quality, heart rate variability, stress, recovery, and activity patterns.
• Uses those signals to spot trends that often show up before a migraine hits.
• Offers guided behavioral suggestions to help users lower risk and improve resilience.

Unlike passive tracking apps, this tool is rooted in the digital therapeutic principles behind CT-132, the first and only FDA-authorized treatment for preventive episodic migraine. That means the insights are not just interesting — they're tied to clinically validated logic about how migraines unfold and how they can be managed alongside medication.

Chief executive Mohit Kumar put it this way: "Helping people improve how they feel daily is core to Ultrahuman's mission. By integrating the underlying principles of Click Therapeutics' digital migraine treatment technology … we're enabling users to track and understand migraine-related patterns in real time, and then go further to turn those insights into actionable guidance."

Why does it matter?

Migraines are no small nuisance. It's a chronic neurological condition with no cure. It's one of the most disabling disorders on the planet and the leading cause of disability among women aged 15 to 49. Most people manage flare-ups with sporadic clinic visits and blunt medications. They're left to guess about trigger factors like stress, sleep, and activity that can cause headaches over days or weeks.

This new tool attempts to flip the script:

• It extends care outside the clinic and into daily life.
• It provides personalized guidance based on your body's signals, not generic advice.
• By combining continuous biometric tracking with evidence-based digital therapeutic logic, users get a sense of what's happening before a migraine strikes.

As Click Therapeutics' founder David Benshoof Klein said, "Our partnership with Ultrahuman will allow us to bring a much-needed personalized migraine solution to people around the world." That's not marketing speak. It's an admission that traditional care often leaves migraine sufferers floating between doctor visits and everyday reality — and that we need smarter tools in the wild.

The context

This partnership lands at the intersection of two big trends in health technology. Wearables like smart rings and watches are no longer curiosities or fitness gadgets. They are becoming serious health sensors capable of capturing rich, continuous data. At the same time, digital therapeutics — software validated through clinical research and recognized by regulators like the FDA — are gaining ground as real medical tools.

Ultrahuman is known for its wearable ecosystem and deep biometric insights. Click Therapeutics is one of the first to take digital therapy mainstream with an FDA-authorized product for migraine. Together, they're showing what happens when regulated clinical rigor meets consumer tech scale.

The Migraine PowerPlug isn't yet a prescription. It's positioned as a wellness experience that users can activate in the Ultrahuman app. It's launching in early 2026 in the United States, Canada, the EU, India, and Australia following initial pilot testing.

In a world where our devices already know our steps, sleep, and stress, this partnership points to a future where they might also help head off a headache before it starts. It's not just clever tech. It's care with a pulse, built for people who need it every day.